United StatesBreaking News

Chevron CEO Mike Wirth discusses the risks for tankers transiting the Strait of Hormuz and says that multiple vessels have been attacked in recent days. "We see risks very real still in that environment," Wirth said on "Bloomberg Surveillance."

Chevron CEO Mike Wirth discusses the impact of the war in Iran on oil prices and global supplies and says the company would not consider paying a toll to traverse the Strait of Hormuz.

Tempus AI (NASDAQ:TEM) announced that the U.S. Food and Drug Administration (FDA) has granted approval for a tumor-only indication for its xT CDx next-generation sequencing platform.

Johnson & Johnson (NYSE:JNJ) reported positive late-stage clinical data for its blood cancer therapy Tecvayli (teclistamab-cqyv), demonstrating significant improvements in survival metrics for patients with relapsed or refractory multiple myeloma.

Bristol Myers Squibb (NYSE:BMY) announced positive late-breaking results from its Phase 3 SUCCESSOR-2 clinical trial, demonstrating that its experimental oral therapy mezigdomide significantly extends the time patients with relapsed or refractory multiple myeloma live without their disease worsening.

Best Buy (NYSE:BBY) announced that its Board of Directors has authorized the payment of a regular quarterly cash dividend of $0.96 per common share, maintaining the electronics retailer's commitment to its ongoing capital return program.

CoStar Group (NASDAQ:CSGP) has entered into a definitive agreement to acquire Zonda, a prominent provider of new home construction data, homebuilder software, and residential marketplaces, for $800 million in cash.

Pfizer (NYSE:PFE) announced unprecedented seven-year follow-up results from its Phase 3 CROWN trial, revealing that its oncology drug Lorbrena significantly extended progression-free survival in patients with a specific, aggressive form of lung cancer.

AbbVie (NYSE:ABBV) has secured authorization from the European Commission for an expanded label of its oncology drug VENCLYXTO (venetoclax) to treat adult patients with previously untreated chronic lymphocytic leukemia (CLL).

The former Chair of Société Générale, Lorenzo Bini Smaghi, has stepped down after more than a decade at the helm. Bini Smaghi says he leaves the lender with 'best in class' governance and a share price 60% higher than when he joined. But he added that the restructuring is not fully over and there are big deals to come. Bini Smaghi joined Lizzy Burden on 'The Pulse'.

Lowe’s Companies (NYSE:LOW) authorized a 4% increase to its quarterly cash dividend, extending a multi-decade track record of annual payout increases and signaling confidence in its steady cash generation capabilities.

Agios Pharmaceuticals (NASDAQ:AGIO) announced that it will discontinue the clinical development of its investigational oral therapy tebapivat for lower-risk myelodysplastic syndromes (LR-MDS) after a Phase 2b study failed to meet its predefined threshold for advancement.